Global Diabetic Neuropathy Market 2014-2018

About Diabetic Neuropathy
Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.
TechNavio's analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, the Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years.
Key Regions
‧ Americas
‧ EMEA
‧ APAC
Key Vendors
‧ Eli Lilly and Co.
‧ Janssen Pharmaceuticals Inc.
‧ Pfizer Inc.
Other Prominent Vendors

‧ Actavis plc
‧ Cephalon Inc.
‧ MEDA Pharma GmbH & Co. KG
Key Market Driver
‧ Increasing Global Diabetic Population.
‧ For a full, detailed list, view our report.
Key Market Challenge
‧ High Failure Rate in Clinical Trials.
‧ For a full, detailed list, view our report.
Key Market Trend
‧ Increasing R&D Activities.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Trends and their Impact
15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Market Share Analysis 2013
15.3 Other Prominent Vendors
16. Key Vendor Analysis
16.1 Pfizer Inc.
16.1.1 Business Overview
16.1.2 Key Information
16.1.3 SWOT Analysis
16.2 Eli Lilly and Company
16.2.1 Business Overview
16.2.2 Business Segmentation
16.2.3 Key Information
16.2.4 SWOT Analysis
16.3 Janssen Pharmaceuticals Inc.
16.3.1 Business Overview
16.3.2 Key Information
16.3.3 SWOT Analysis
17. Pipeline Analysis
17.1 Phase III Analysis
17.2 Phase II Analysis
17.3 Phase I Analysis
17.4 Discontinued Projects
17.5 Projects on Hold
17.6 Promising Pipeline Molecules
17.6.1 Phase III Promising Pipeline Molecules
17.6.2 Phase II Promising Pipeline Molecules
17.7 Other First-in-class Pipeline Molecules:
18. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Diabetic Neuropathy Market 2013-2018 (US$ billion)
Exhibit 3: Global Diabetic Neuropathy Market by Geographical Segmentation 2013
Exhibit 4: Eli Lilly and Company: Business Segmentation
Exhibit 5: Diabetic Neuropathy Pipeline Snapshot 2013
Exhibit 6: Discontinued Pipeline Molecules on the basis of MOA